ADMA Biologics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ADMA Biologics, Inc. on March 2, 2026. The report discloses a significant capital allocation event involving an accelerated share repurchase (ASR) agreement.
Key Financial Metrics and Transaction Details
- Transaction Type: Accelerated Share Repurchase (ASR) Agreement.
- Counterparty: JPMorgan Chase Bank, National Association.
- Total Commitment: $125 million.
- Initial Share Delivery: Approximately 6.4 million shares (representing ~80% of expected total).
- Reference Price: $15.57 per share (closing price on February 27, 2026).
- Funding Source: Borrowings under the Company's existing $225 million revolving credit facility.
- Program Context: Part of a previously announced $500 million share repurchase program authorized on May 7, 2025.
The filing does not provide specific revenue, profit, cash flow, or margin data for the reporting period, as this is a current report focused on a specific corporate event rather than periodic financial results.
Material Changes and Settlement Terms
The total number of shares ultimately repurchased will be determined at final settlement based on the average of the daily volume-weighted average price (VWAP) of the Common Stock during the term of the agreement, less an agreed discount. The transaction is expected to be completed within five months. At final settlement, the Company may receive additional shares or, under limited circumstances, may be required to deliver shares or make a cash payment.
Outlook, Risks, and Management Commentary
Management has executed this transaction to return capital to shareholders under the existing $500 million authorization. The filing notes that the upfront payment of $125 million will be funded via the revolving credit facility, which may impact the Company's available liquidity under that facility. No specific forward-looking guidance on revenue or earnings was included in this document.
Key Facts for Investor Verification
- Verify the remaining capacity under the $225 million revolving credit facility after the $125 million drawdown.
- Monitor the final settlement date (expected within five months) to determine the actual share count repurchased and the final average price.
- Confirm the total remaining authorization under the $500 million share repurchase program following this $125 million commitment.
- Review the press release (Exhibit 99.1) for any additional commentary on the Company's strategic rationale.